Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~  * Metastatic disease~* Scheduled to begin treatment with capecitabine at the University of California, San Francisco (UCSF) Cancer Center, San Francisco General Hospital, or Cornell Medical Center~* No concurrent hand-foot syndrome (HFS) due to other medications~  * Prior HFS due to other medications allowed provided that the symptoms have been completely resolved for ≥ 4 weeks prior to study entry~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after completion of study therapy~* Able to participate in study procedures and quality-of-life evaluations and willing to comply with study requirements~* Non-English speaking patients are allowed provided they demonstrate adequate understanding of the study rationale and procedures and can give voluntary consent with the aid of a translator~* No clinically significant cardiac or peripheral vascular disease or symptom, including any of the following:~  * History of myocardial infarction~ * Congestive heart failure~ * Cardiac arrhythmias (including atrial fibrillation)~ * Cardiac or vascular bypass~ * Uncontrolled hypertension~ * Unstable angina~ * Undiagnosed arrhythmias or claudication~* No Alzheimer disease, Parkinson disease, or active psychiatric disease~* Not currently smoking~  * Patients who are former smokers must have stopped smoking ≥ 6 months prior to study entry~* No known hypersensitivity to nicotine patches~PRIOR CONCURRENT THERAPY:~* At least 6 months since prior and no other concurrent nicotine patches~* Prior chemotherapy allowed, except capecitabine for treatment of metastatic disease~* Concurrent other symptomatic treatment for hand-foot syndrome (HFS) (e.g., usual skin care, topical moisturizers, ice packs, pain medications) allowed~* No concurrent pyridoxine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Prior to initiation of capecitabine (Type: EXPERIMENTAL): Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
- Arm B: After hand-foot syndrome symptoms appear (Type: EXPERIMENTAL): Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues